Badawi Jasmin Katrin
Medical Faculty Mannheim of The Ruprecht-Karls-University of Heidelberg Mannheim, Germany.
Am J Clin Exp Urol. 2023 Feb 25;11(1):1-11. eCollection 2023.
Prostate cancer is one of the most common cancers in men. Despite the development of diverse therapeutic agents for different types and stages, the progression or spread of the disease is inevitable. Another problem is the development of resistance of cancer cells to available therapeutics. Therefore, additional medicaments are urgently needed. Resveratrol is a polyphenolic phytoalexin found in numerous plants and fruits like red grapes or blueberries. Resveratrol possesses antiproliferative, anti-angiogenic and anticancer activities well proven in different types of cancer including prostate cancer. To date, it is not used clinically due to poor solubility, low bioavailability, and other limiting factors. In order to overcome these limitations, novel nanoparticle-based formulations were developed over the past years. In this review article, studies about the effect of resveratrol on prostate cancer cells are discussed focusing especially on those studies using nanotechnology. An electronic literature research was performed utilizing PubMed in August 2022. Scientific publications, which examine resveratrol using nanotechnology, are discussed. The studies clearly indicate that resveratrol-loaded nanoparticles exhibited a remarkable anti-cancer activity in various hormone-sensitive and hormone-insensitive prostate cancer cell lines including docetaxel-resistant prostate-cancer cells. The types of nanoparticles that were used varied and influenced the outcome. Additionally, the meaning of the surface functionality of the nanoparticles is emphasized. No reduction of the anti-proliferative activity of resveratrol was shown when used encapsulated. Additionally, synergistic effects of resveratrol and docetaxel were proven. Resveratrol-loaded nanoparticles, especially when combined, may represent the next generation of anticancer substances. However, further in vivo/clinical studies are necessary to confirm their clinical effectiveness.
前列腺癌是男性中最常见的癌症之一。尽管针对不同类型和阶段开发了多种治疗药物,但疾病的进展或扩散仍不可避免。另一个问题是癌细胞对现有治疗方法产生耐药性。因此,迫切需要更多药物。白藜芦醇是一种多酚类植物抗毒素,存在于许多植物和水果中,如红葡萄或蓝莓。白藜芦醇具有抗增殖、抗血管生成和抗癌活性,在包括前列腺癌在内的不同类型癌症中已得到充分证实。迄今为止,由于溶解度差、生物利用度低和其他限制因素,它尚未用于临床。为了克服这些限制,在过去几年中开发了新型的基于纳米颗粒的制剂。在这篇综述文章中,讨论了关于白藜芦醇对前列腺癌细胞作用的研究,尤其关注那些使用纳米技术的研究。2022年8月利用PubMed进行了电子文献检索。讨论了使用纳米技术研究白藜芦醇的科学出版物。这些研究清楚地表明,负载白藜芦醇的纳米颗粒在各种激素敏感和激素不敏感的前列腺癌细胞系中表现出显著的抗癌活性,包括对多西他赛耐药的前列腺癌细胞。所使用的纳米颗粒类型各不相同,且会影响结果。此外,强调了纳米颗粒表面功能的意义。封装使用时,白藜芦醇的抗增殖活性没有降低。此外,还证实了白藜芦醇和多西他赛的协同作用。负载白藜芦醇的纳米颗粒,尤其是联合使用时,可能代表下一代抗癌物质。然而,需要进一步的体内/临床研究来证实它们的临床有效性。